A long-acting vasopressin analog for septic shock: Brilliant idea or dangerous folly?

Pediatric Critical Care Medicine

Volumn 5, Issue 2, 2004, Pages 188-189

  Berg, Robert A ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; LYPRESSIN; TERLIPRESSIN; VASOCONSTRICTOR AGENT;

CHILD; HUMAN; NOTE; SEPTIC SHOCK;

CHILD; HUMANS; LYSINE VASOPRESSIN; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS;

EID: 3843063649     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/01.PCC.0000121301.62216.0D     Document Type: Editorial

References (16)

1. Peters MJ, Booth RA, Petros AJ. Terlipressin bolus induces systemic vasoconstriction in septic shock. Pediatr Crit Care Med 2004; 5:112-115
2. Matok I, Leibovitch L, Vardi A, et al: Terlipressin as rescue therapy for intractable hypotension during neonatal septic shock. Pediatr Crit Care Med 2004; 5:116-118
3. Ioannou GN, Doust J, Rockey DC: Systematic review: Terlipressin in acute oesophageal variceal haemorrhage. Aliment Pharmacol Ther 2003; 17:53-64
4. Ioannou G, Doust J, Rockey DC: Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev 2003;1(CD002147)
5. O'Brien A, Clapp L, Singer M: Terlipressin for norepinephrine-resistant septic shock. Lancet 2002; 359:1209-1210
6. Westphal M, Stubbe H, Sielenkämper AW, et al: Terlipressin dose response in healthy and endotoxemic sheep: Impact on cardiopulmonary performance and global oxygen transport. Intensive Care Med 2003; 29:301-308
7. Bernadich C, Bandi JC, Melin P, et al: Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension. Hepatology 1998; 27:351-356
8. Douglas JG, Forrest JA, Prowse CV, et al: Effects of lysine vasopressin and glypressin on the fibrinolytic system in cirrhosis. Gut 1979; 20:565-567
9. Solanki P, Chawla A, Garg R, et al: Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebocontrolled clinical trial. J Gastroenterol Hepatol 2003; 18:152-156
10. Colle I, Durand F, Pessione F, et al: Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: A retrospective analysis. J Gastroenterol Hepatol 2002; 17:882-888
11. Landry DW, Levin HR, Gallant EM, et al: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95:1122-1125
12. Robin JK, Oliver JA, Landry DW: Vasopressin deficiency in the syndrome of irreversible shock. J Trauma 2003; 54:S149-S154
13. Tsuneyoshi I, Boyle WA. Vasopressin: New uses for an old drug. Contemp Crit Care 2003; 1:1-11
14. Morales DL, Garrido MJ, Madigan JD, et al: A double-blind randomized trial: Prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg 2003; 75:926-930
15. Carcillo JA, Fields AI: Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med 2002; 30:1365-1378
16. Ceneviva G, Paschall JA, Maffei F, et al: Hemodynamic support in fluid-refractory pediatric septic shock. Pediatrics 1998; 102:e19